WALTHAM, MA • 2022-06-03

BostonGene to Present at the 2022 American Society of Clinical Oncology Annual Meeting

5 min to read

BostonGene today announced that three abstracts have been accepted for poster presentations and one abstract has been accepted for online publication for the 2022 ASCO Annual Meeting (ASCO)
WALTHAM, MA, June 3, 2022

BostonGene today announced that three abstracts have been accepted for poster presentations and one abstract has been accepted for online publication for the 2022 ASCO Annual Meeting (ASCO), which will be held June 3 – 7, 2022, at McCormick Place Convention Center in Chicago, IL.  BostonGene will also exhibit at booth 27087.

“We are excited to share our latest research at ASCO that underscores the critical need for innovative analytical tools to understand the composition and activity of the tumor and the microenvironment to improve treatment outcomes for cancer patients,” said Nathan Fowler MD, Chief Medical Officer at BostonGene.

Details about the abstracts selected for presentation can be found below:

Abstract Number: 4591
Title: A classification system for urothelial carcinoma (UC) defined by genomic drivers and the tumor microenvironment (TME) is predictive of immunotherapy response
Date and Time: Saturday, June 4 | 1:15 PM – 4:15 PM
Location: McCormick Place Convention Center, Hall A
Poster Number: 82
Speaker: Krystle Nomie, PhD, BostonGene

This presentation underscores the application of BostonGene’s transcriptome-based classification platform, previously reported by Bagaev et al., to identify TME subtypes for urothelial carcinoma that are predictive of response to immunotherapy.

Abstract Number: 3020
Title: A clinical AI-driven multiplex immunofluorescence imaging pipeline to characterize tumor microenvironment heterogeneity
Date and Time: Sunday, June 5 | 8:00 AM – 11:00 AM*
Location: McCormick Place Convention Center, Hall A
Poster Number: 12
Speaker: Zhongmin Xiang, PhD, BostonGene

*A follow-up poster discussion highlighting the AI-driven BostonGene MxIF analytical pipeline and its automated microenvironment characterization across cancers will take place from 4:30 PM – 6:00 PM in Hall D2

This presentation highlights the importance of innovative MxIF platforms to characterize tumor heterogeneity at single-cell resolution with high accuracy across many cancers.

Abstract Number: 3142
Title: A digital imaging analysis (DIA) platform for identifying tertiary lymphoid structures (TLS) in lung adenocarcinoma (LUAD)
Date and Time: Sunday, June 5 | 8:00 AM – 11:00 AM
Location: McCormick Place Convention Center, Hall A
Poster Number: 134
Speaker: Ekaterina Postovalova, PhD, BostonGene

This presentation demonstrates the ability of novel and cutting-edge imaging technologies in the BostonGene pipeline to detect tertiary lymphoid structures (TLS) in lung cancer.

Online publication abstract:

Abstract Number: e20624
Title: Longitudinal Molecular Analysis of Tumor Exome and Transcriptome to Evaluate Clonal Evolution and Identify Novel Therapeutic Targets in Thymoma

This abstract highlights the importance of a longitudinal comprehensive molecular analysis using genomic and transcriptomic sequencing to improve the understanding of rare thymic epithelial tumors.

Research conducted with Massachusetts General Hospital

For more information, please visit the 2022 ASCO Annual Meeting website. The abstracts will be published online in the Journal of Clinical Oncology supplement for the ASCO Annual Meeting Proceedings.

About BostonGene Corporation

BostonGene has a mission to provide transformative, AI-integrated molecular analytics and biomarker discovery for precision matching of therapies to improve the lives of patients living with cancer and other immune-related diseases. BostonGene’s service model provides customized client solutions using a multi-omic approach prioritized for real-world impact, including optimized standard-of-care therapies, accelerated research and cost-effective, measurable results. BostonGene’s tests reveal key drivers of each patient’s unique disease profile, including an in-depth profile of the immune microenvironment, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene’s tests generate a personalized roadmap for therapeutic decision-making for each patient. For more information, visit BostonGene at http://www.BostonGene.com.

Erin O’Reilly

Senior Director

+1-617-283-2285

Erin.Oreilly@BostonGene.com